Form 8-K - Current report:
SEC Accession No. 0001193125-24-000247
Filing Date
2024-01-02
Accepted
2024-01-02 08:06:00
Documents
14
Period of Report
2024-01-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d676865d8k.htm   iXBRL 8-K 24129
2 EX-99.1 d676865dex991.htm EX-99.1 6379
6 GRAPHIC g676865g0102065800099.jpg GRAPHIC 4960
  Complete submission text file 0001193125-24-000247.txt   158366

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cort-20240102.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cort-20240102_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cort-20240102_pre.xml EX-101.PRE 10812
8 EXTRACTED XBRL INSTANCE DOCUMENT d676865d8k_htm.xml XML 3273
Mailing Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025
Business Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 650.688.8803
CORCEPT THERAPEUTICS INC (Filer) CIK: 0001088856 (see all company filings)

EIN.: 770487658 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50679 | Film No.: 24500300
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)